Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track BTAI with free AI briefings, catalyst countdowns, and dilution alerts.

BTAI · BioXcel Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

Chapter 11 bankruptcy. BioXcel Therapeutics filed for Chapter 11 bankruptcy protection on Aug 28, 2026 (8-K, Item 1.03). The stock now trades over the counter as BTAIQ. Read the filing
$12.8M Cash on Hand
4.3mo Cash Runway
0% Short Interest
Follow BTAI by email Get an email when BTAI reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about BTAI, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Dexmedetomidine Hydrochloride
FDA approved Apr 2022 · Igalmi
Delirium Phase 2 · NCT04382170 Withdrawn
BXCL501 Opioid Use Disorder Phase 1/2 · NCT05712707 Active not recruiting
Talabostat (BXCL701) Prostate Cancer Phase 1/2 · NCT03910660 Completed
Sublingual film containing Dexmedetomidine Agitation,Psychomotor Phase 1/2 · NCT04251910 Completed
Dexmedetomidine (DEX) for sublingual (SL)… Alcohol Use Disorder (AUD) Phase 1 · NCT06335407 Recruiting
Dexmedetomidine (DEX) for sublingual (SL)… Alcohol Use Disorder (AUD) Phase 1 · NCT06335407 Recruiting
Talabostat Mesylate Cancer of Pancreas Early Phase 1 · NCT04123574 Withdrawn

Also used in these trials (approved or third-party drugs, not BTAI's own candidates): Dexmedetomidine, Lorazepam, Pembrolizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

BTAI holds $12.8M in cash and short-term investments (as of Jun 30, 2026) and burns about $9M/quarter from operations, an estimated runway of 4.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 90 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BTAI files for a raise →

👥 Who Owns BTAI

Insiders 2.1% Institutions 17.1% Public and other holders 80.8%
HolderTypeShares% of sharesAs of
Millennium Management LLC Institution (13G, 5%+) 1,835,192 5.86% 2025-12-31
Oaktree Capital Management LP Institution (13F) 1,380,248 4.41% 2026-06-30
Vanguard Capital Management LLC Institution (13F) 919,545 2.94% 2026-06-30
Vimal Mehta
CEO and President, Director · +1,313 options
Insider 550,285 1.76% 2026-06-15
Oaktree Fund Advisors, LLC Institution (13F) 245,585 0.78% 2026-06-30
Geode Capital Management, LLC Institution (13F) 242,251 0.77% 2026-06-30
Blackrock Inc. Institution (13F) 179,433 0.57% 2026-06-30
UBS Group AG Institution (13F) 158,065 0.50% 2026-06-30
Citadel Advisors Llc Institution (13F) 149,220 0.48% 2026-06-30
Vanguard Fiduciary Trust Co Institution (13F) 136,937 0.44% 2026-06-30
State Street Corporation Institution (13F) 92,118 0.29% 2026-06-30
Javier Rodriguez
Chief Legal Officer, Senior Vice Preside · +212 options
Insider 26,838 0.09% 2026-06-15

Share count 31,305,499 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-08-12
filed 2026-08-14
Atkins Susan E.
Option award (A) 17,000 – –
2026-06-15
filed 2026-06-17
Steinhart Richard I
Option exercise (M) 35 – –
2026-06-15
filed 2026-06-17
Steinhart Richard I
Option exercise (M) 35 – 26,335
2026-05-20
filed 2026-05-22
Yocca Frank
Sale (S) 6,845 $1.09 26,175
2026-05-20
filed 2026-05-22
Rodriguez Javier
Sale (S) 6,560 $1.08 26,803

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-11-14 IGALMI sNDA — — —

Browse all historical PDUFA outcomes →

Get the full BTAI picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BTAI and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.